GlobeNewswire

Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA

Del

FDA Confirms Vitaros Regulatory Pathway

 Company Seeking Partner to Develop Vitaros in U.S.

Company Evaluating Strategic Alternatives

SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the outcome of its end-of-review meeting with the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Vitaros(TM) (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction. 

The preliminary end-of-review meeting minutes support a plan to address issues cited by the FDA in its February 15, 2018 Complete Response Letter (CRL) for the Vitaros NDA.  Specifically, the FDA confirmed during the meeting that the company should develop a new Vitaros formulation that reduces the concentration of DDAIP.HCl from 2.5% to 0.5% in order to address the tumor promotion and partner transference safety concerns noted in the CRL.  The FDA also confirmed that two new Phase 3 clinical efficacy trials with the reformulated product should be conducted prior to resubmitting the NDA and that the trials should include an assessment of the potential risk of enhanced sexually transmitted infections with the new formulation. In addition, the FDA requested certain pharmacokinetic assessments that we expect can be completed as part of the requested Phase 3 program and any additional clinical or commercial safety data generated prior to a resubmission.  Lastly, the FDA stated that the Chemistry, Manufacturing and Control (CMC) section in the resubmission will need to be updated with data generated during development of the new formulation.

The FDA previously issued a CRL for the Vitaros NDA, indicating that it could not approve the NDA for Vitaros in its present form, identifying deficiencies related to CMC and whether the modest treatment effect of Vitaros outweighed certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation. 

"While we are pleased that the FDA has outlined a clear regulatory pathway for Vitaros, which we believe provides a path to approval in the U.S., the cost and timeline associated with a reformulation effort and completing additional phase 3 clinical trials exceeds our current resources and our ability to raise additional capital.  Therefore, we have initiated discussions with interested parties for the U.S. Vitaros rights to enable its continued development and potential approval in exchange for financial terms commensurate with a development stage asset.  In parallel, the Board of Directors has determined that Apricus should evaluate strategic alternatives or other business combinations, with the goal of maximizing shareholder value," said Richard Pascoe, Chief Executive Officer.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates: Vitaros, a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan); and RayVa, a product candidate which has completed a Phase 2a clinical trial for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com.

Vitaros(TM) is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States.  RayVa(TM) is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: the potential to enter into a U.S. partnership regarding Vitaros; Apricus' ability to identify and conclude strategic transactions or other business combinations; and the timing of any clinical and non-clinical trials and studies to address the FDA's concerns and whether the results of such trials and studies would be sufficient to overcome the deficiencies raised in the CRL. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside of Apricus' control, including, but not limited to: Apricus' financial position and need for additional capital to fund its operations, which may be adversely impacted if Apricus is unable to maintain the continued listing of its common stock on the Nasdaq stock market; a partnership with respect to U.S. Vitaros and any larger strategic transaction or other business combination may not be available on acceptable terms or at all; Apricus' ability to address any conditions for approvability of Vitaros raised by the FDA in the CRL; the risks of any additional adverse safety or other data arising from the sales and use of Vitaros in certain countries in Europe and elsewhere; competition in the ED market; and other risks identified by Apricus in its reports filed with the Securities and Exchange Commission (SEC). These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.

CONTACT: 

Matthew Beck
mbeck@troutgroup.com
Solebury Trout
(646) 378-2933




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Dubai Airports partners with XDubai for one-of-a-kind stunt embodying Dubai’s ambitious spirit19.2.2019 15:46:00Pressemelding

Stunt showcases refreshed DXB brand’s vision of pushing boundaries and creating new experiences DUBAI, United Arab Emirates, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dubai Airports has partnered with action sports brand XDubai to deliver an incredible one-of-a-kind stunt by Emirati athlete and skydiver Mohammed Baker, as part of the new DXB brand which aims to position the world’s busiest international airport as a major destination for culture, hospitality, and entertainment. The stunning showcase, captured in a short film released by both Dubai Airports and XDubai, just following the refreshed brand reveal recently, captures what is believed to be the world’s longest skydive swoop under a fixed structure. As showcased in the video, skydiver Mohammed Baker jumps out of a helicopter with a parachute emblazoned with the new DXB brand, gliding through the Dubai sky before performing one of the world’s longest skydive swoops - measuring 112m - under the Sheikh Zayed Road bridge. With Downtown Du

New PubMatic Research Finds Mobile In-App Monetization Spurred by Video and Header Bidding, Though Challenges Remain19.2.2019 15:00:00Pressemelding

Company releases Q4 2018 QMI report, highlighting key trends in mobile advertising growth REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today released its fourth Quarterly Mobile Index (QMI) of 2018. The report highlights key trends influencing mobile advertising growth, allowing publishers and advertisers to make smarter decisions around their programmatic strategies. Advertisers are increasingly attracted to the enhanced targeting and increased customer engagement of mobile in-app, with many buyers opting for programmatic transaction methods for this inventory (Forrester Consulting). PubMatic’s Q4 2018 QMI Report found that in-app video ad spend was up over 200 percent year-over-year in 2018 as buyers embrace in-stream opportunities. Header bidding technology is also beginning to take hold within the in-app environment, with impression volumes growing more than 300X year-over-year in

Canada Rare Earth Reinvigorates a South American Rare Earth Mine and Processing Opportunity19.2.2019 14:45:00Pressemelding

VANCOUVER, British Columbia, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Canada Rare Earth Corp. (“Canada Rare Earth” or the “Company”) (TSX.V: LL) is pleased to announce that it has re-established discussions and momentum with the owners (the “Owners”) of an advanced prospective rare earth property situated in South America (the “Property”). The recent dialogue has resulted in an agreement outlined in a non-binding letter of intent (the “2019 LOI”) which is significantly different from the original letter of intent announced on October 17, 2017 (the “2017 LOI”). The 2019 LOI is simpler in many regards. For example, under the 2019 LOI Canada Rare Earth will purchase the rare earth concentrate for either sale or further processing onsite, whereas the 2017 LOI provided for more of a joint venture collaboration with joint management and cross ownership of the prospective mine and processing facilities. The 2019 LOI and the 2017 LOI are consistent in that: The Owners will prepare and transport a 50-

Cloudian Solves Backup Challenges for European Managed Services Provider19.2.2019 14:00:00Pressemelding

Provides Limitlessly Scalable, Cost-effective Storage Foundation for Data Protection SAN MATEO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cloudian today announced that Systemec, a managed services provider specializing in health care and logistics in the Netherlands and Germany, has deployed Cloudian’s HyperStore object storage platform to address the backup challenges of growing data volumes. Cloudian enables Systemec to protect data from multiple applications, prevent the scheduling problems it previously faced and achieve increased cost efficiency. Continued Data Growth Threatens to Overwhelm Backup Windows Founded in 2007, Systemec runs two data centers in The Netherlands and one in Germany under a unique cross-border strategy that supports more than 500 customers. As the amount of data the company manages rapidly increased, Systemec realized it needed a cost-effective solution to store and secure customer data. “This growth raised concerns about accommodating the future data volum

VistaJet Partners With Scuderia Ferrari Mission Winnow for the 2019 Formula One World Championship19.2.2019 11:33:00Pressemelding

Supporting the team with the most efficient global travel solution LONDON, Feb. 19, 2019 (GLOBE NEWSWIRE) -- VistaJet, the first and only global business aviation company, announces its partnership with the Scuderia Ferrari Mission Winnow team as its Official Supplier of private jet travel. With the tight schedule of the race calendar and often only days between Grands Prix, VistaJet will support the team to optimize their travel and transfer times throughout the 2019 Formula One season. In an industry where speed and efficiency are fundamental, the Scuderia Ferrari Mission Winnow team will further utilize time off track to arrive in optimum condition. Having raced competitively with Ferrari for many years and as an official driver in the FIA World Endurance Championship, WEC, VistaJet’s Founder and Chairman Thomas Flohr knows the demands of racing and the intense focus required to perform under such pressure. With his Ferrari 488 GTE, Thomas achieved second place at the 24h of Le Mans

ACC Opens New Europe Headquarters in Brussels19.2.2019 11:00:00Pressemelding

Giuseppe Marletta appointed managing director to serve European in-house legal community Brussels, Belgium, Feb. 19, 2019 (GLOBE NEWSWIRE) -- The Association of Corporate Counsel (ACC), a global legal association representing more than 45,000 in-house counsel employed by over 10,000 organizations in 85 countries, has opened its first office in Brussels. It will serve as the nucleus of ACC in Europe, led by new managing director Giuseppe Marletta. Marletta, former general manager of the International Association of Young Lawyers (AIJA), has an extensive background in pan-European advocacy and high-level operations management. ACC’s hiring of Marletta and new European office will allow the organization to offer more and more varied services to in-house lawyers on the Continent. ACC Europe serves about 2,500 lawyers, both in and out of the European Union. Celebrating 25 years in 2019, it is one of ACC’s oldest chapters. This year will see the 2019 Annual Conference in Edinburgh, the 2019